These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1047 related items for PubMed ID: 26404747

  • 1. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A, Scavone C, Vitale C, Sportiello L, Rossi F, Rosano GM, Coats AJ.
    Int J Cardiol; 2015 Dec 01; 200():15-9. PubMed ID: 26404747
    [Abstract] [Full Text] [Related]

  • 2. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF).
    Deswal A, Richardson P, Bozkurt B, Mann DL.
    J Card Fail; 2011 Aug 01; 17(8):634-42. PubMed ID: 21807324
    [Abstract] [Full Text] [Related]

  • 3. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
    Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Messig M, Vincent J, Girerd N, Bakris G, Pitt B, Zannad F.
    Circ Heart Fail; 2014 Jan 01; 7(1):51-8. PubMed ID: 24297687
    [Abstract] [Full Text] [Related]

  • 4. Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials.
    Pamporis K, Karakasis P, Sagris M, Zarifis I, Bougioukas KI, Pagkalidou E, Milaras N, Samaras A, Theofilis P, Fragakis N, Tousoulis D, Xanthos T, Giannakoulas G.
    Curr Probl Cardiol; 2024 Jul 01; 49(7):102615. PubMed ID: 38692445
    [Abstract] [Full Text] [Related]

  • 5. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ, Howard PA.
    Ann Pharmacother; 2005 Jan 01; 39(1):68-76. PubMed ID: 15590870
    [Abstract] [Full Text] [Related]

  • 6. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
    Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, Speziale G, Gaudio C.
    Int J Cardiol; 2015 Dec 01; 200():25-9. PubMed ID: 26404748
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B, EMPHASIS-HF Investigators.
    J Am Coll Cardiol; 2013 Oct 22; 62(17):1585-93. PubMed ID: 23810881
    [Abstract] [Full Text] [Related]

  • 8. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis.
    Jhund PS, Talebi A, Henderson AD, Claggett BL, Vaduganathan M, Desai AS, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Solomon SD, McMurray JJV.
    Lancet; 2024 Sep 21; 404(10458):1119-1131. PubMed ID: 39232490
    [Abstract] [Full Text] [Related]

  • 9. Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials.
    Kapelios CJ, Murrow JR, Nührenberg TG, Montoro Lopez MN.
    Heart Fail Rev; 2019 May 21; 24(3):367-377. PubMed ID: 30618017
    [Abstract] [Full Text] [Related]

  • 10. Eplerenone in chronic heart failure with depressed systolic function.
    Volterrani M, Iellamo F.
    Int J Cardiol; 2015 Dec 01; 200():12-4. PubMed ID: 26044084
    [Abstract] [Full Text] [Related]

  • 11. Review article: eplerenone: an underused medication?
    Abuannadi M, O'Keefe JH.
    J Cardiovasc Pharmacol Ther; 2010 Dec 01; 15(4):318-25. PubMed ID: 20876342
    [Abstract] [Full Text] [Related]

  • 12. Aldosterone receptor antagonists decrease mortality and cardiovascular hospitalizations in chronic heart failure with reduced left ventricular ejection fraction, but not in chronic heart failure with preserved left ventricular ejection fraction: a meta-analysis of randomized controlled trials.
    DE Vecchis R, Ariano C.
    Minerva Cardioangiol; 2017 Aug 01; 65(4):427-442. PubMed ID: 27958695
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?
    Mitter SS, Shah SJ.
    Curr Atheroscler Rep; 2015 Nov 01; 17(11):64. PubMed ID: 26408016
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy.
    Rossignol P, Ménard J, Fay R, Gustafsson F, Pitt B, Zannad F.
    J Am Coll Cardiol; 2011 Nov 01; 58(19):1958-66. PubMed ID: 22032706
    [Abstract] [Full Text] [Related]

  • 17. Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial.
    Lewis EF, Claggett B, Shah AM, Liu J, Shah SJ, Anand I, O'Meara E, Sweitzer NK, Rouleau JL, Fang JC, Desai AS, Retta TM, Solomon SD, Heitner JF, Stamos TD, Boineau R, Pitt B, Pfeffer MA.
    Circ Heart Fail; 2018 Mar 01; 11(3):e004457. PubMed ID: 29664406
    [Abstract] [Full Text] [Related]

  • 18. The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF.
    Naser N, Durak-Nalbantic A, Sabanovic-Bajramovic N, Karic A.
    Med Arch; 2023 Apr 01; 77(2):105-111. PubMed ID: 37260796
    [Abstract] [Full Text] [Related]

  • 19. Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT.
    Patel RB, Shah SJ, Fonarow GC, Butler J, Vaduganathan M.
    Curr Heart Fail Rep; 2017 Aug 01; 14(4):217-222. PubMed ID: 28647918
    [Abstract] [Full Text] [Related]

  • 20. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
    Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators.
    N Engl J Med; 2003 Apr 03; 348(14):1309-21. PubMed ID: 12668699
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.